

ELECTRONIC SUPPORTING INFORMATION

For

**Chemoselective Synthesis of α -Fluoromethyl Amides *via* the
Controlled Addition of LiCH₂F to *N*-Aryl and *N*-Alkyl Isocyanates**

Davide Castiglione,^a Alberto Nardi,^a Margherita Miele,^a Laura Castoldi^{b*} and Vittorio Pace^{c,d*}

^a University of Turin, Department of Chemistry, Via P. Giuria 7 – 10125 Turin (Italy).

^b University of Milan - Department of Pharmaceutical Sciences, General and Organic Chemistry Section “A. Marchesini” – Via Venezian 21, 20133 Milan, Italy. e-mail: laura.castoldi@unimi.it

^c University of Rome "La Sapienza", Department of Chemistry - P.le A. Moro, 5, 00185 Rome (Italy). e-mail: vittorio.pace@uniroma1.it

^d University of Vienna, Department of Pharmaceutical Sciences, Division of Pharmaceutical Chemistry - Josef-Holaubek-Platz 2, 1090, Vienna (Austria) - e-mail: vittorio.pace@univie.ac.at

Instrumentation and General Analytical Methods	2
Synthesis of starting materials	3
General procedures for the synthesis of α-fluoroacetamides	3
Characterization and spectral data of all products	4
Copies of ¹H, ¹³C and ¹⁹F -NMR copies of all compounds	17
HPLC Analysis Data for chiral compounds	69
References	73


Instrumentation and General Analytical Methods

^1H - and ^{13}C -NMR spectra were recorded with a Bruker Avance Neo 400 spectrometer (400 MHz for ^1H , 100 MHz for ^{13}C , 376 MHz for ^{19}F) and a Jeol ECZR600 spectrometer (600 MHz for ^1H , 150 MHz for ^{13}C , 564 MHz for ^{19}F). The center of the (residual) solvent signal was used as internal standard which was related to TMS with δ 7.26 ppm (^1H in CDCl_3), δ 77.2 ppm (^{13}C in CDCl_3), δ 2.50 ppm (^1H) and δ 39.5 ppm (^{13}C) for $\text{DMSO-}d_6$. Spin-spin coupling constants (J) are given in Hz.

All reactions were performed under an inert atmosphere of argon by using standard schlenk techniques. THF and Et_2O were distilled over Na/benzophenone. Chemicals were purchased from SigmaAldrich, Acros, Alfa Aesar, Fluorochem and TCI Europe. Non-commercially available starting materials were prepared as detailed below and are indicated with the descriptor **nn-sm**, being **nn** the corresponding final compound in the manuscript. Solutions were evaporated under reduced pressure with a rotary evaporator. For column chromatography, silica Gel 60 (0.04-0.063 mm) was used. TLC was carried out on aluminium sheets precoated with silica gel 60F254 (Merchery-Nagel, Merk); the spots were visualized under UV light ($\lambda = 254$ nm) and/or KMnO_4 (aq.) was used as revealing system.

Synthesis of starting materials

Most of isocyanates employed as starting materials are commercially available and were purchased from Thermofisher, VWR, Sigma-Aldrich, TCI and BLDPharm. Those which are not available were prepared as previously reported (see below). *All isocyanates were distilled or recrystallized prior to their use in order to eliminate traces of amines.*



General procedures for the synthesis of α -fluoroacetamides

General procedure for 2-fluoroacetamides from *non*-sterically hindered aryl isocyanates (GP1)


Under Ar atmosphere, to a solution of isocyanate (1.0 equiv) in dry THF/Et₂O 1:1 (20 mL) and fluoroiodomethane (5.2 equiv) cooled down to -78 °C, MeLi (1.6 M in Et₂O, 5 equiv) was quickly added and the mixture was immediately quenched (within 20 seconds) with a saturated solution of NH₄Cl_(aq.) (3 mL). The organic phase was extracted with Et₂O (3 x 10 mL), washed with brine, dried over anhydrous Na₂SO₄ and the solvent was finally removed under reduced pressure. The final product was purified by column chromatography on silica gel as described below.

General procedure for 2-fluoroacetamides from alkyl- and sterically hindered aryl isocyanates (GP2)

Under Ar atmosphere, to a solution isocyanate (1.0 equiv) in dry THF/Et₂O 1:1 (5 mL) and fluoroiodomethane (3.0 equiv) cooled down to -78 °C, MeLi (1.6 M in Et₂O, 2.8 equiv) was added dropwise and the mixture was stirred for 5 minutes. Subsequently, a saturated solution of NH₄Cl_(aq.) (3 mL) was added. The organic phase was extracted with Et₂O (3 x 10 mL), washed with brine, dried over anhydrous Na₂SO₄ and the solvent was finally removed under reduced pressure. The final product was purified by column chromatography on silica gel as described below.

Characterization and spectral data of all products

2-fluoro-*N*-(4-fluorophenyl)acetamide (2)



By following the general procedure 1 (GP1), starting from 4-fluorophenyl isocyanate (137.1 mg, 0.11 mL, 1.0 mmol, 1.0 equiv), fluoroiodomethane (828.4 mg, 0.35 mL, 5.2 mmol, 5.2 equiv) and MeLi (3.12 mL of a solution 1.6 M in Et₂O, 5.0 mmol, 5.0 equiv) in dry THF/Et₂O (1:1 v/v, 20 mL), compound **2**^[4] was obtained in 86% yield (147.1 mg) as a white solid (m.p.: 98 °C, lit^[1] 99-100 °C) after chromatography on silica gel (7:3 v/v, petroleum ether/ethyl acetate).


¹H-NMR (400 MHz, CDCl₃) δ: 7.90 (s, 1H), 7.59 – 7.49 (m, 2H), 7.06 (t, J = 8.6 Hz, 2H), 4.93 (d, J = 47.4 Hz, 2H).

¹³C-NMR (100 MHz, CDCl₃) δ: 165.59 (d, J = 16.2 Hz), 160.01 (d, J = 244.6 Hz), 132.53 (d, J = 3.0 Hz), 122.10 (d, J = 8.0 Hz), 116.04 (d, J = 22.6 Hz), 80.33 (d, J = 187.5 Hz), 29.85.

¹⁹F-NMR (376 MHz, CDCl₃) δ: -116.79 (dq, J = 8.2, 4.1 Hz), -222.38 (td, J = 47.2, 5.0 Hz).

HRMS (ESI), m/z: calc. for C₈H₇F₂NOH⁺: 172,0568 [M+H]⁺; found 172,0562.

1,3-bis(4-fluorophenyl)urea (2a)



Compound **2a**^[2] was obtained as a by-product in yield up to 64% during the optimization tests, as a violet solid (m.p.: 261-262 °C, lit^[3] 260-262 °C) after chromatography on silica gel (6:4 v/v, petroleum ether/ethyl acetate).


¹H-NMR (600 MHz, DMSO-*d*₆) δ: 8.68 (s, 2H), 7.46 (dt, J = 8.8, 3.9 Hz, 4H), 7.11 (t, J = 8.8 Hz, 4H).

¹³C-NMR (150 MHz, DMSO-*d*₆) δ: 157.37 (d, J = 237.9 Hz), 152.75, 136.03 (d, J = 2.7 Hz), 120.03 (d, J = 7.8 Hz), 115.27 (d, J = 21.7 Hz).

¹⁹F-NMR (376 MHz, DMSO-*d*₆) δ: -121.46 (m).

HRMS (ESI), m/z: calc. for C₁₃H₁₀F₂N₂OH⁺: 249,0834 [M+H]⁺; found 249,0838.

1,3,5-tris(4-fluorophenyl)biuret (2b)



Compound **2b**^[4] was obtained as a by-product in yield up to 26% during the optimization tests, as a white solid (m.p.: 178 °C, lit^[5] 175.5-179 °C) after chromatography on silica gel (6:4, v/v, petroleum ether/ethyl acetate).


¹H-NMR (400 MHz, CDCl₃) δ: 8.76 (s, 2H), 7.38 – 7.30 (m, 2H), 7.30 – 7.24 (m, 4H), 7.23 – 7.14 (m, 2H), 6.99 – 6.87 (m, 4H).

¹³C-NMR (100 MHz, CDCl₃) δ: 163.18 (d, J = 251.4 Hz), 159.83 (d, J = 244.2 Hz), 153.60, 133.08 (d, J = 2.9 Hz), 132.31 (d, J = 3.4 Hz), 131.85 (d, J = 9.0 Hz), 122.77 (d, J = 8.0 Hz), 117.76 (d, J = 22.9 Hz), 115.88 (d, J = 22.6 Hz).

¹⁹F-NMR (376 MHz, CDCl₃) δ: -109.97 (p, J = 7.6 Hz), -117.55 (br s).

HRMS (ESI), m/z: calc. for C₂₀H₁₄F₃N₃O₂H⁺: 386,1111 [M+H]⁺; found 386,1116.

2-bromo-*N*-(4-fluorophenyl)acetamide (**2c**)




Compound **2c**^[6] was obtained as a by-product in yield up to 18% during the optimization tests, as a white solid (m.p.: 138 °C, lit^[7] 137-138) after chromatography on silica gel (7:3 v/v, petroleum ether/ethyl acetate).

¹H-NMR (400 MHz, CDCl₃) δ: 8.17 (br, 1H), 7.53 – 7.44 (m, 2H), 7.10 – 6.99 (m, 2H), 4.01 (s, 2H).

¹³C-NMR (100 MHz, CDCl₃) δ: 163.63, 160.04 (d, J = 244.9 Hz), 133.04 (d, J = 2.9 Hz), 122.18 (d, J = 8.0 Hz), 115.97 (d, J = 22.7 Hz), 29.47.

HRMS (ESI), m/z: calc. for C₈H₇BrFNOH⁺: 231,9768 [M+H]⁺; found 231,9761.

2-fluoro-*N*-(4-iodophenyl)acetamide (**3**)



By following the general procedure 1 (GP1), starting from 4-iodophenyl isocyanate (245.0 mg, 1.0 mmol, 1.0 equiv), fluoroiodomethane (828.4 mg, 0.35 mL, 5.2 mmol, 5.2 equiv) and MeLi (3.12 mL of a solution 1.6 M in Et₂O, 5.0 mmol, 5.0 equiv) in dry THF/Et₂O (1:1 v/v, 20 mL), compound **3**^[8] was obtained in 81% yield (225.8 mg) as white solid (m.p.: 157-158 °C) after chromatography on silica gel (75:25 v/v, petroleum ether/ethyl acetate).


¹H-NMR (400 MHz, CDCl₃) δ: 7.88 (br, 1H), 7.67 (d, J = 8.7 Hz, 1H), 7.36 (d, J = 8.8 Hz, 1H), 4.92 (d, J = 47.4 Hz, 2H).

¹³C-NMR (100 MHz, CDCl₃) δ: 165.5 (s), 138.3 (s), 136.3 (s), 122.0 (s), 88.7 (s), 80.3 (d, J = 187.9 Hz).

¹⁹F-NMR (376 MHz, CDCl₃) δ: -222.2 (td, J = 47.6, 5.3 Hz).

HRMS (ESI), m/z: calc. for C₈H₇FINOH⁺: 279,9629 [M+H]⁺; found 279,9632.

2-fluoro-*N*-(*p*-tolyl)acetamide (**4**)



By following the general procedure 1 (GP1), starting from *p*-tolyl isocyanate (133.2 mg, 0.13 mL, 1.0 mmol, 1.0 equiv), fluoroiodomethane (828.4 mg, 0.35 mL, 5.2 mmol, 5.2 equiv) and MeLi (3.12 mL of a solution 1.6 M in Et₂O, 5.0 mmol, 5.0 equiv) in dry THF/Et₂O (1:1 v/v, 20 mL), compound **4**^[9] was obtained in 86%

yield (143.8 mg) as white solid (m.p.: 112 °C, lit^[1] 112-113 °C) after chromatography on silica gel (75:25 v/v, petroleum ether/ethyl acetate).


¹H-NMR (400 MHz, CDCl₃) δ: 7.88 (br, 1H), 7.44 (d, *J* = 8.4 Hz, 1H), 7.16 (d, *J* = 8.2 Hz, 2H), 4.91 (d, *J* = 47.4 Hz, 2H), 2.33 (s, 3H).

¹³C-NMR (100 MHz, CDCl₃) δ: 165.5 (d, *J* = 16.3 Hz), 134.5 (d, *J* = 101.0 Hz), 129.8 (s), 120.3 (s), 80.3 (d, *J* = 187.8 Hz), 21.0 (s).

¹⁹F-NMR (376 MHz, CDCl₃) δ: -222.1 (td, *J* = 47.2, 5.1 Hz).

HRMS (ESI), *m/z*: calc. for C₉H₁₀FNOH⁺: 168,0819 [M+H]⁺; found 168,0813

N-(2-ethylphenyl)-2-fluoroacetamide (5)



By following the general procedure 1 (GP1), starting from 2-ethylphenyl isocyanate (147,2 mg, 0.14 mL, 1.0 mmol, 1.0 equiv), fluoroiodomethane (828.4 mg, 0.35 mL, 5.2 mmol, 5.2 equiv) and MeLi (3.12 mL of a solution 1.6 M in Et₂O, 5.0 mmol, 5.0 equiv) in dry THF/Et₂O (1:1 v/v, 20 mL), compound 5^[1] was obtained in 85% yield (154.0 mg) as white solid (m.p.: 63 °C, lit^[1] 63-64 °C) after chromatography on silica gel (80:20 v/v, petroleum ether/ethyl acetate).


¹H-NMR (400 MHz, CDCl₃) δ: 7.91 (br, 1H), 7.90 (dd, *J* = 8.5, 1.4 Hz, 1H), 7.27 – 7.23 (m, 1H), 7.20 – 7.16 (m, 1H), 4.97 (d, *J* = 47.4 Hz, 2H), 2.64 (q, *J* = 7.6 Hz, 2H), 1.26 (t, *J* = 7.6 Hz, 3H).

¹³C-NMR (150 MHz, CDCl₃) δ: 165.8 (d, *J* = 16.1 Hz), 135.0 (s), 133.7 (s), 128.9 (s), 127.0 (s), 126.2 (s), 123.3 (s), 80.6 (d, *J* = 187.3 Hz), 24.3 (s), 14.0 (s).

¹⁹F-NMR (376 MHz, CDCl₃) δ: -222.1 (td, *J* = 47.2, 5.1 Hz).

HRMS (ESI), *m/z*: calc. for C₁₀H₁₃FNOH⁺: 182,0976 [M+H]⁺; found 182,0971.

2-fluoro-*N*-(4-(methylthio)phenyl)acetamide (6)



By following the general procedure 1 (GP1), starting from 4-(methylthio)phenyl isocyanate (165.2 mg, 0.14 mL, 1.0 mmol, 1.0 equiv), fluoroiodomethane (828.4 mg, 0.35 mL, 5.2 mmol, 5.2 equiv) and MeLi (3.12 mL of a solution 1.6 M in Et₂O, 5.0 mmol, 5.0 equiv) in dry THF/Et₂O (1:1 v/v, 20 mL), compound 6^[1] was obtained in 87% yield (173.3 mg) as white solid (m.p.: 96 °C, lit^[1] 97-98 °C) after chromatography on silica gel (75:25 v/v, petroleum ether/ethyl acetate).


¹H-NMR (400 MHz, CDCl₃) δ: 7.87 (br, 1H), 7.42 (d, *J* = 8.6 Hz, 2H), 7.17 (d, *J* = 8.7 Hz, 2H), 4.83 (d, *J* = 47.4 Hz, 2H), 2.40 (s, 3H).

¹³C-NMR (100 MHz, CDCl₃) δ: 165.5 (d, *J* = 16.2 Hz), 134.5 (d, *J* = 88.8 Hz), 127.9 (s), 120.8 (s), 80.3 (d, *J* = 187.5 Hz), 16.5 (s).

¹⁹F-NMR (376 MHz, CDCl₃) δ: -222.2 (td, *J* = 47.8, 5.2 Hz).

HRMS (ESI), *m/z*: calc. for C₉H₁₀FNOSH⁺: 200,0540 [M+H]⁺; found 200,0534.

2-fluoro-*N*-(naphthalen-1-yl)acetamide (**7**)



By following the general procedure 1 (GP1), starting from 1-naphthyl isocyanate (169.2 mg, 1.0 mmol, 1.0 equiv), fluoroiodomethane (828.4 mg, 0.35 mL, 5.2 mmol, 5.2 equiv) and MeLi (3.12 mL of a solution 1.6 M in Et₂O, 5.0 mmol, 5.0 equiv) in dry THF/Et₂O (1:1 v/v, 20 mL), compound **7**^[10] was obtained in 84% yield (170.7 mg) as white solid (m.p.: 128 °C) after chromatography on silica gel (75:25 v/v, petroleum ether/ethyl acetate).


¹H-NMR (400 MHz, CDCl₃) δ: 8.41 (br, 1H), 8.01 (d, *J* = 7.5 Hz, 1H), 7.90 (d, *J* = 7.2 Hz, 1H), 7.86 (d, *J* = 8.0 Hz, 1H), 7.75 (d, *J* = 8.2 Hz, 1H), 7.53 (m, *J* = 17.5, 7.5 Hz, 3H), 5.07 (d, *J* = 47.4 Hz, 2H).

¹³C-NMR (100 MHz, CDCl₃) δ: 166.2 (d, *J* = 16.9 Hz), 134.2 (s), 130.8 (s), 129.0 (s), 127.0 (s), 126.7 (s), 126.5 (s), 126.3 (s), 125.8 (s), 120.9 (s), 120.3 (s), 80.76 (d, *J* = 187.3 Hz).

¹⁹F-NMR (376 MHz, CDCl₃) δ: -222.16 (td, *J* = 47.5, 5.2 Hz).

HRMS (ESI), *m/z*: calc. for C₁₂H₁₀FNOH⁺: 204,0819 [M+H]⁺; found 204,0822.

(*R*)-2-fluoro-*N*-(1-phenylethyl)acetamide ((*R*)-**9**)



By following the general procedure 2 (GP2), starting from (*R*)-1-phenylethylisocyanate (147,2 mg, 0.14 mL, 1.0 mmol, 1.0 equiv), fluoroiodomethane (479.8 mg, 0.20 mL, 3.0 mmol, 3.0 equiv) and MeLi (1.75 mL of a solution 1.6 M in Et₂O, 2.8 mmol, 2.8 equiv) in dry THF/Et₂O (1:1 v/v, 5 mL), compound (*R*)-**9**^[11] was obtained in 87% yield (157.5 mg) as white solid (m.p.: 78 °C, lit^[11] 79-80 °C) after chromatography on silica gel (72:28 v/v, petroleum ether/ethyl acetate).


¹H-NMR (400 MHz, CDCl₃) δ: 7.38 – 7.21 (m, 5H), 6.58 (br, 1H), 5.18 (p, 1H, *J* = 7.0 Hz), 4.83 (dd, 1H, *J* = 14.2, 8.6 Hz), 4.68 (dd, 1H, *J* = 14.2, 8.6 Hz), 1.52 (d, *J* = 6.9 Hz, 3H).

¹³C-NMR (100 MHz, CDCl₃) δ: 166.70 (d, *J* = 17.3 Hz), 142.52, 128.85, 127.70, 126.24, 80.33 (d, *J* = 185.9 Hz), 48.41, 21.77.

¹⁹F-NMR (376 MHz, CDCl₃) δ: -224.42 (td, *J* = 47.6, 3.3 Hz).

HRMS (ESI), *m/z*: calc. for C₁₀H₁₂FNOH⁺: 182,0976 [M+H]⁺; found 182,0980.

(*S*)-2-fluoro-*N*-(1-phenylethyl)acetamide ((*S*)-**9**)



By following the general procedure 2 (GP2), starting from (*S*)-1-phenylethylisocyanate (147,2 mg, 0.14 mL, 1.0 mmol, 1.0 equiv), fluoroiodomethane (479.8 mg, 0.20 mL, 3.0 mmol, 3.0 equiv) and MeLi (1.75 mL of a solution 1.6 M in Et₂O, 2.8 mmol, 2.8 equiv) in dry THF/Et₂O (1:1 v/v, 5 mL), compound (*S*)-**9**^[12] was obtained in 83% yield (151.5 mg) as white solid (m.p.: 77.5 °C) after chromatography on silica gel (72:28 v/v, petroleum ether/ethyl acetate).


¹H-NMR (400 MHz, CDCl₃) δ: 7.38 – 7.21 (m, 5H), 6.58 (br, 1H), 5.18 (p, 1H, *J* = 7.0 Hz), 4.83 (dd, 1H, *J* = 14.2, 8.6 Hz), 4.68 (dd, 1H, *J* = 14.2, 8.6 Hz), 1.52 (d, *J* = 6.9 Hz, 3H).

¹³C-NMR (100 MHz, CDCl₃) δ: 166.70 (d, *J* = 17.3 Hz), 142.52, 128.85, 127.70, 126.24, 80.33 (d, *J* = 185.9 Hz), 48.41, 21.77.

¹⁹F-NMR (376 MHz, CDCl₃) δ: -224.42 (td, *J* = 47.6, 3.3 Hz).

HRMS (ESI), m/z: calc. for C₁₀H₁₂FNOH⁺: 182,0976 [M+H]⁺; found 182,0973.

2-fluoro-N-(1-phenylethyl)acetamide ((rac)-9)



By following the general procedure 2 (GP2), starting from 1-phenylethylisocyanate (147,2 mg, 1.0 mmol, 1.0 equiv), fluoroiodomethane (479.8 mg, 0.20 mL, 3.0 mmol, 3.0 equiv) and MeLi (1.75 mL of a solution 1.6 M in Et₂O, 2.8 mmol, 2.8 equiv) in dry THF/Et₂O (1:1 v/v, 5 mL), compound **(rac)-9**^[13] was obtained in 84% yield (154.0 mg) as white solid (m.p.: 68-69 °C) after chromatography on silica gel (72:28 v/v, petroleum ether/ethyl acetate).


¹H-NMR (400 MHz, CDCl₃) δ: 7.38 – 7.21 (m, 5H), 6.58 (br, 1H), 5.18 (p, 1H, J=7.0 Hz), 4.83 (dd, 1H, J=14.2, 8.6 Hz), 4.68 (dd, 1H, J=14.2, 8.6 Hz), 1.52 (d, J = 6.9 Hz, 3H).

¹³C-NMR (100 MHz, CDCl₃) δ: 166.70 (d, J = 17.3 Hz), 142.52, 128.85, 127.70, 126.24, 80.33 (d, J = 185.9 Hz), 48.41, 21.77.

¹⁹F-NMR (376 MHz, CDCl₃) δ: -224.42 (td, J = 47.6, 3.3 Hz).

HRMS (ESI), m/z: calc. for C₁₀H₁₂FNOH⁺: 182,0976 [M+H]⁺; found 182,0972.

(S)-2-fluoro-N-(1-phenylpropyl)acetamide ((S)-10)



By following the general procedure 2 (GP2), starting from (S)-1-phenylpropylisocyanate (147,2 mg, 1.0 mmol, 1.0 equiv), fluoroiodomethane (479.8 mg, 0.20 mL, 3.0 mmol, 3.0 equiv) and MeLi (1.75 mL of a solution 1.6 M in Et₂O, 2.8 mmol, 2.8 equiv) in dry THF/Et₂O (1:1 v/v, 5 mL), compound **(S)-10** was obtained in 88% yield (171.8 mg) as white solid (m.p.: 81 °C) after chromatography on silica gel (72:28 v/v, petroleum ether/ethyl acetate).


¹H-NMR (400 MHz, CDCl₃) δ: 7.40 – 7.18 (m, 5H), 6.57 (br, 1H), 4.93 (q, J = 7.8 Hz, 1H), 4.89 – 4.58 (m, 2H), 1.94 – 1.80 (m, 2H), 0.89 (t, J = 7.4 Hz, 3H).

¹³C-NMR (100 MHz, CDCl₃) δ: 166.90 (d, J = 17.1 Hz), 141.47, 128.81, 127.67, 126.70, 80.35 (d, J = 185.8 Hz), 54.53, 29.15, 10.76.

¹⁹F-NMR (376 MHz, CDCl₃) δ: -224.28 (td, J = 47.3, 3.5 Hz).

HRMS (ESI), m/z: calc. for C₁₁H₁₄FNOH⁺: 196,1132 [M+H]⁺; found 196,1127.

2-fluoro-N-(1-phenylpropyl)acetamide ((rac)-10)



By following the general procedure 2 (GP2), starting from (S)-1-phenylpropylisocyanate (147,2 mg, 1.0 mmol, 1.0 equiv), fluoroiodomethane (479.8 mg, 0.20 mL, 3.0 mmol, 3.0 equiv) and MeLi (1.75 mL of a solution 1.6 M in Et₂O, 2.8 mmol, 2.8 equiv) in dry THF/Et₂O (1:1 v/v, 5 mL), compound **(rac)-10** was obtained in 89% yield (173.7 mg) as white solid (m.p.: 81 °C) after chromatography on silica gel (72:28 v/v, petroleum ether/ethyl acetate).


¹H-NMR (400 MHz, CDCl₃) δ: 7.40 – 7.18 (m, 5H), 6.57 (br, 1H), 4.93 (q, J = 7.8 Hz, 1H), 4.89 – 4.58 (m, 2H), 1.94 – 1.80 (m, 2H), 0.89 (t, J = 7.4 Hz, 3H).

¹³C-NMR (100 MHz, CDCl₃) δ: 166.90 (d, J = 17.1 Hz), 141.47, 128.81, 127.67, 126.70, 80.35 (d, J = 185.8 Hz), 54.53, 29.15, 10.76.

¹⁹F-NMR (376 MHz, CDCl₃) δ: -224.28 (td, J = 47.3, 3.5 Hz).

HRMS (ESI), m/z: calc. for C₁₁H₁₄FNOH⁺: 196,1132 [M+H]⁺; found 196,1138.

((R)-2-fluoro-N-(1-(naphthalen-1-yl)ethyl)acetamide ((R)-11)



By following the general procedure 2 (GP2), starting from (R)-1-(1-naphthyl)ethylisocyanate (197.2 mg, 0.18 mL, 1.0 mmol, 1.0 equiv), fluoroiodomethane (479.8 mg, 0.20 mL, 3.0 mmol, 3.0 equiv) and MeLi (1.75 mL of a solution 1.6 M in Et₂O, 2.8 mmol, 2.8 equiv) in dry THF/Et₂O (1:1 v/v, 5 mL), compound **(R)-11** was obtained in 82% yield (189.7 mg) as white solid (m.p.: 112 °C,) after chromatography on silica gel (72:28 v/v, petroleum ether/ethyl acetate).


¹H-NMR (400 MHz, CDCl₃) δ: 8.13 (d, J = 7.8 Hz, 1H), 7.89 (dd, J = 7.9, 1.8 Hz, 1H), 7.85 – 7.79 (m, 1H), 7.60 – 7.50 (m, 3H), 7.50 – 7.43 (m, 1H), 6.72 (br, 1H), 6.04 (p, J = 7.1 Hz, 1H), 4.86 (q, J = 17.6 Hz, 1H), 4.70 (q, 1H), 1.71 (d, J = 17.6 Hz, J = 6.8 Hz, 3H).

¹³C-NMR (100 MHz, CDCl₃) δ: 166.49 (d, J = 17.4 Hz), 130.97, 128.90, 128.56, 126.66, 125.93, 125.23, 123.13, 122.65, 80.19 (d, J = 185.9 Hz), 20.92. J = 17.6 Hz

¹⁹F-NMR (376 MHz, CDCl₃) δ: -224.49 (td, J = 47.4, 3.2 Hz).

HRMS (ESI), m/z: calc. for C₁₄H₁₄FNOH⁺: 232,1132 [M+H]⁺; found 232,1135.

((S)-2-fluoro-N-(1-(naphthalen-1-yl)ethyl)acetamide ((S)-11)



By following the general procedure 2 (GP2), starting from (S)-1-(1-naphthyl)ethylisocyanate (197.2 mg, 0.18 mL, 1.0 mmol, 1.0 equiv), fluoroiodomethane (479.8 mg, 0.20 mL, 3.0 mmol, 3.0 equiv) and MeLi (1.75 mL of a solution 1.6 M in Et₂O, 2.8 mmol, 2.8 equiv) in dry THF/Et₂O (1:1 v/v, 5 mL), compound **(S)-11** was obtained in 84% yield (194.3 mg) as white solid (m.p.: 112.5 °C) after chromatography on silica gel (72:28 v/v, petroleum ether/ethyl acetate).

Scale-up to 20 mmol:

By following the general procedure 2 (GP2), starting from (S)-1-(1-naphthyl)ethylisocyanate (3944.0 mg, 3.6 mL, 20.0 mmol, 1.0 equiv), fluoroiodomethane (9596.0 mg, 4.0 mL, 60.0 mmol, 3.0 equiv) and MeLi (35.0 mL of a solution 1.6 M in Et₂O, 56.0 mmol, 2.8 equiv) in dry THF/Et₂O (1:1 v/v, 100 mL), compound **(S)-11** was obtained in 83% yield (3838 mg) as white solid (m.p.: 112.5 °C) after chromatography on silica gel (72:28 v/v, petroleum ether/ethyl acetate).


¹H-NMR (400 MHz, CDCl₃) δ: 8.13 (d, J = 7.8 Hz, 1H), 7.89 (dd, J = 7.9, 1.8 Hz, 1H), 7.85 – 7.79 (m, 1H), 7.60 – 7.50 (m, 3H), 7.50 – 7.43 (m, 1H), 6.72 (br, 1H), 6.04 (p, J = 7.1 Hz, 1H), 4.86 (q, J = 17.6 Hz, 1H), 4.70 (q, 1H), 1.71 (d, J = 17.6 Hz, J = 6.8 Hz, 3H).

¹³C-NMR (100 MHz, CDCl₃) δ: 166.49 (d, J = 17.4 Hz), 130.97, 128.90, 128.56, 126.66, 125.93, 125.23, 123.13, 122.65, 80.19 (d, J = 185.9 Hz), 20.92. J = 17.6 Hz

¹⁹F-NMR (376 MHz, CDCl₃) δ: -224.49 (td, J = 47.4, 3.2 Hz).

HRMS (ESI), m/z: calc. for C₁₄H₁₄FNOH⁺: 232,1132 [M+H]⁺; found 232,1138.

2-fluoro-*N*-(1-(naphthalen-1-yl)ethyl)acetamide ((*rac*)-**11**)



By following the general procedure 2 (GP2), starting from (*S*)-1-(1-naphthyl)ethylisocyanate (197.23 mg, 0.18 mL, 1.0 mmol, 1.0 equiv), fluoroiodomethane (479.8 mg, 0.20 mL, 3.0 mmol, 3.0 equiv) and MeLi (1.75 mL of a solution 1.6 M in Et₂O, 2.8 mmol, 2.8 equiv) in dry THF/Et₂O (1:1 v/v, 5 mL), compound (*rac*)-**11** was obtained in 86% yield (199.0 mg) as white solid (m.p.: 104 °C) after chromatography on silica gel (72:28 v/v, petroleum ether/ethyl acetate).


¹H-NMR (600 MHz, CDCl₃) δ: 8.13 (d, *J* = 7.8 Hz, 1H), 7.89 (dd, *J* = 7.9, 1.8 Hz, 1H), 7.85 – 7.79 (m, 1H), 7.60 – 7.50 (m, 3H), 7.50 – 7.43 (m, 1H), 6.72 (br, 1H), 6.04 (p, *J* = 7.1 Hz, 1H), 4.86 (q, *J* = 17.6 Hz, 1H), 4.70 (q, 1H), 1.71 (d, *J* = 17.6 Hz, *J* = 6.8 Hz, 3H).

¹³C-NMR (150 MHz, CDCl₃) δ: 166.49 (d, *J* = 17.4 Hz), 130.97, 128.90, 128.56, 126.66, 125.93, 125.23, 123.13, 122.65, 80.19 (d, *J* = 185.9 Hz), 20.92. *J* = 17.6 Hz

¹⁹F-NMR (376 MHz, CDCl₃) δ: -224.49 (td, *J* = 47.4, 3.2 Hz).

HRMS (ESI), *m/z*: calc. for C₁₄H₁₄FNOH⁺: 232,1132 [M+H]⁺; found 232,1127.

N-benzhydryl-2-fluoroacetamide (**12**)



By following the general procedure 2 (GP2), starting from benzhydrylisocyanate (225.3 mg, 0.2 mL, 1.0 mmol, 1.0 equiv), fluoroiodomethane (479.8 mg, 0.20 mL, 3.0 mmol, 3.0 equiv) and MeLi (1.75 mL of a solution 1.6 M in Et₂O, 2.8 mmol, 2.8 equiv) in dry THF/Et₂O (1:1 v/v, 5 mL), compound **12**^[14] was obtained in 90% yield (218.7 mg) as white solid (m.p.: 108 °C) after chromatography on silica gel (7:3 v/v, petroleum ether/ethyl acetate).


¹H-NMR (400 MHz, CDCl₃) δ: 7.46 – 7.21 (m, 10H), 6.91 (br, 1H), 6.33 (d, *J* = 8.4 Hz, 1H), 4.87 (d, *J* = 47.4 Hz, 2H).

¹³C-NMR (100 MHz, CDCl₃) δ: 166.91, 140.90, 128.91, 127.87, 127.49, 80.45 (d, *J* = 185.9 Hz), 56.40.

¹⁹F-NMR (376 MHz, CDCl₃) δ: -224.67 (td, *J* = 47.4, 3.3 Hz).

HRMS (ESI), *m/z*: calc. for C₁₅H₁₄FNOH⁺: 244,1132 [M+H]⁺; found 244,1128.

2-fluoro-*N*-(2-(3-(prop-1-en-2-yl)phenyl)propan-2-yl)acetamide (**13**)



By following the general procedure 2 (GP2), starting from 3-isopropenyl- α,α -dimethylbenzyl isocyanate (201.3 mg, 0.20 mL, 1.0 mmol, 1.0 equiv), fluoroiodomethane (479.8 mg, 0.20 mL, 3.0 mmol, 3.0 equiv) and MeLi (1.75 mL of a solution 1.6 M in Et₂O, 2.8 mmol, 2.8 equiv) in dry THF/Et₂O (1:1 v/v, 5 mL), compound **13** was obtained in 85% yield (200.0 mg) as white solid (m.p.: 98 °C) after chromatography on silica gel (85:15 v/v, petroleum ether/ethyl acetate).


¹H-NMR (400 MHz, CDCl₃) δ: 7.50 (s, 1H), 7.40 – 7.27 (m, 3H), 6.55 (br, 1H), 5.36 (s, 1H), 5.10 (s, 1H), 4.72 (d, *J* = 47.6 Hz, 2H), 2.16 (s, 3H), 1.78 (s, 6H).

¹³C-NMR (100 MHz, CDCl₃) δ: 166.54 (d, J = 15.8 Hz), 146.23, 143.53, 141.68, 128.51, 124.40, 123.95, 122.03, 112.81, 80.48 (d, J = 187.1 Hz), 56.23, 29.08, 22.00.

¹⁹F-NMR (376 MHz, CDCl₃) δ: -221.03 (td, J = 47.6, 4.0 Hz).

HRMS (ESI), m/z: calc. for C₁₄H₁₈FNOH⁺: 236,1445 [M+H]⁺; found 236,1451.

N,N'-(1,3-phenylenebis(propane-2,2-diyl))bis(2-fluoroacetamide) (**14**)



By following the general procedure 2 (GP2), starting from 1,3-bis(2-isocyanatopropan-2-yl)benzene (244.3 mg, 0.23 mL, 1.0 mmol, 1.0 equiv), fluoroiodomethane (959.6 mg, 0.40 mL, 6.0 mmol, 3.0 equiv) and MeLi (3.50 mL of a solution 1.6 M in Et₂O, 5.6 mmol, 2.8 equiv) in dry THF/Et₂O (1:1 v/v, 5 mL), compound **14** was obtained in 81% yield (253.0 mg) as yellow solid (m.p.: 108 °C) after chromatography on silica gel (4:6 v/v, petroleum ether/ethyl acetate).


¹H-NMR (400 MHz, CDCl₃) δ: 7.44 (t, J = 2.0 Hz, 1H), 7.37 – 7.24 (m, 3H), 6.53 (br, 2H), 4.70 (d, J = 47.6 Hz, 2H), 1.76 (s, 12H).

¹³C-NMR (100 MHz, CDCl₃) δ: 166.56 (d, J = 15.9 Hz), 146.49, 128.79, 123.52, 121.27, 80.43 (d, J = 187.1 Hz), 56.35, 29.06.

¹⁹F-NMR (376 MHz, CDCl₃) δ: -221.01 (td, J = 47.7, 4.0 Hz).

HRMS (ESI), m/z: calc. for C₁₆H₂F₂N₂O₂H⁺: 313,1722 [M+H]⁺; found 313,1718.

N-benzyl-2-fluoroacetamide (**15**)



By following the general procedure 2 (GP2), starting from benzylisocyanate (133.2 mg, 0.12 mL, 1.0 mmol, 1.0 equiv), fluoroiodomethane (479.8 mg, 0.20 mL, 3.0 mmol, 3.0 equiv) and MeLi (1.75 mL of a solution 1.6 M in Et₂O, 2.8 mmol, 2.8 equiv) in dry THF/Et₂O (1:1 v/v, 5 mL), compound **15**^[15] was obtained in 88% yield (147.1 mg) as white solid (m.p.: 70-72 °C, lit^[16] 71-72 °C) after chromatography on silica gel (7:3 v/v, petroleum ether/ethyl acetate).


¹H-NMR (400 MHz, CDCl₃) δ: 7.41 – 7.25 (m, 5H), 6.70 (br, 1H), 4.82 (d, J = 47.4 Hz, 2H), 4.50 (d, J = 5.9 Hz, 2H).

¹³C-NMR (100 MHz, CDCl₃) δ: 167.57 (d, J = 17.3 Hz), 137.51, 128.88, 127.93, 127.85, 80.35 (d, J = 186.0 Hz), 42.96.

¹⁹F-NMR (376 MHz, CDCl₃) δ: -224.50 (td, J = 47.7, 3.2 Hz).

HRMS (ESI), m/z: calc. for C₉H₁₀FNOH⁺: 168,0819 [M+H]⁺; found 168,0824.

2-fluoro-*N*-(4-methoxybenzyl)acetamide (**16**)



By following the general procedure 2 (GP2), starting from 4-Methoxybenzyl isocyanate (163,2 mg, 0.14 mL, 1.0 mmol, 1.0 equiv), fluoroiodomethane (479.8 mg, 0.20 mL, 3.0 mmol, 3.0 equiv) and MeLi (1.75 mL of a

solution 1.6 M in Et₂O, 2.8 mmol, 2.8 equiv) in dry THF/Et₂O (1:1 v/v, 5 mL), compound **16** was obtained in 81% yield (159.7 mg) as yellow solid (m.p.: 100-102 °C) after chromatography on silica gel (6:4 v/v, petroleum ether/ethyl acetate).


¹H-NMR (400 MHz, CDCl₃) δ: 7.22 (d, J = 8.6 Hz, 2H), 6.87 (d, J = 8.7 Hz, 2H), 6.61 (br, 1H), 4.80 (d, J = 47.4 Hz, 2H), 4.43 (d, J = 5.8 Hz, 2H), 3.79 (s, 3H).

¹³C-NMR (100 MHz, CDCl₃) δ: 167.44 (d, J = 17.3 Hz), 159.32, 129.60, 129.34, 114.26, 80.35 (d, J = 185.9 Hz), 42.46.

¹⁹F-NMR (376 MHz, CDCl₃) δ: -224.82 (td, J = 47.4, 3.2 Hz).

HRMS (ESI), m/z: calc. for C₁₀H₁₂FNO₂H⁺: 198,0925 [M+H]⁺; found 198,0928.

2-fluoro-N-phenethylacetamide (17)



By following the general procedure 2 (GP2), starting from phenethyl isocyanate (147.2 mg, 0.14 mL, 1.0 mmol, 1.0 equiv), fluoroiodomethane (479.8 mg, 0.20 mL, 3.0 mmol, 3.0 equiv) and MeLi (1.75 mL of a solution 1.6 M in Et₂O, 2.8 mmol, 2.8 equiv) in dry THF/Et₂O (1:1 v/v, 5 mL), compound **17**^[17] was obtained in 86% yield (155.8 mg) as white solid (m.p.: 56-58 °C, lit^[13] 57-58 °C) after chromatography on silica gel (65:35 v/v, petroleum ether/ethyl acetate).


¹H-NMR (400 MHz, CDCl₃) δ: 7.37 – 7.17 (m, 5H), 6.41 (br, 1H), 4.75 (d, J = 47.4 Hz, 2H), 3.60 (q, J = 6.8 Hz, 2H), 2.86 (t, J = 7.1 Hz, 2H).

¹³C-NMR (100 MHz, CDCl₃) δ: 167.61 (d, J = 17.1 Hz), 138.44, 128.78, 128.75, 126.74, 80.31 (d, J = 185.9 Hz), 40.05, 35.67.

¹⁹F-NMR (376 MHz, CDCl₃) δ: -224.67 (td, J = 47.2, 3.2 Hz).

HRMS (ESI), m/z: calc. for C₁₀H₁₂FNOH⁺: 182,0976 [M+H]⁺; found 182,0982.

2-fluoro-N-(2-(thiophen-2-yl)ethyl)acetamide (18)



By following the general procedure 2 (GP2), starting from 2-(2-Thienyl)ethyl isocyanate (153.2 mg, 1.0 mmol, 1.0 equiv), fluoroiodomethane (479.8 mg, 0.20 mL, 3.0 mmol, 3.0 equiv) and MeLi (1.75 mL of a solution 1.6 M in Et₂O, 2.8 mmol, 2.8 equiv) in dry THF/Et₂O (1:1 v/v, 5 mL), compound **18** was obtained in 89% yield (166.6 mg) as yellow solid (m.p.: 72 °C) after chromatography on silica gel (65:35 v/v, petroleum ether/ethyl acetate).


¹H-NMR (400 MHz, CDCl₃) δ: 7.15 (dd, J = 5.1, 1.2 Hz, 1H), 6.93 (dd, J = 5.1, 3.4 Hz, 1H), 6.84 (dt, J = 3.4, 1.0 Hz, 1H), 6.57 (br, 1H), 4.75 (d, J = 47.3 Hz, 2H), 3.59 (q, J = 6.6 Hz, 2H), 3.06 (t, J = 6.8 Hz, 2H).

¹³C-NMR (100 MHz, CDCl₃) δ: 167.69 (d, J = 17.1 Hz), 140.72, 127.14, 125.48, 124.13, 80.27 (d, J = 185.9 Hz), 40.21, 29.79.

¹⁹F-NMR (376 MHz, CDCl₃) δ: -224.90 (td, J = 47.5, 3.4 Hz).

HRMS (ESI), m/z: calc. for C₈H₁₀FNOSH⁺: 188,0540 [M+H]⁺; found 188,0535.

(2-fluoroacetyl)-L-phenylalanine *tert*-butyl ester (**19**)



By following the general procedure 2 (GP2), starting from L-phenylalanine *tert*-butyl ester isocyanate (147.3 mg, 1.0 mmol, 1.0 equiv), fluoroiodomethane (479.8 mg, 0.20 mL, 3.0 mmol, 3.0 equiv) and MeLi (1.75 mL of a solution 1.6 M in Et₂O, 2.8 mmol, 2.8 equiv) in dry THF/Et₂O (1:1 v/v, 5 mL), compound **19** was obtained in 82% yield (230.4 mg) as white solid (m.p.: 187 °C) after chromatography on silica gel (7:3 v/v, petroleum ether/ethyl acetate).


¹H-NMR (600 MHz, CDCl₃) δ: δ 7.34 – 7.25 (m, 2H), 7.25 (m, 1H), 7.21 – 7.13 (m, 2H), 6.76 (br d, J = 7.8 Hz, 1H), 4.81 (qd, J = 6.2, 1.2 Hz, 1H), 4.78 (d, J = 47.3 Hz, 2H), 3.12 (d, J = 6.2 Hz, 2H), 1.41 (s, 9H).

¹³C-NMR (150 MHz, CDCl₃) δ: 170.12, 167.23 (d, J = 17.4 Hz), 135.88, 129.57, 128.64, 127.28, 82.87, 80.20 (d, J = 186.2 Hz), 53.09, 38.32, 28.06.

¹⁹F-NMR (376 MHz, CDCl₃) δ: -224.67 (td, J = 47.4, 3.3 Hz).

HRMS (ESI), m/z: calc. for C₁₅H₁₀FNO₃H⁺: 282,1500 [M+H]⁺; found 282,1506.

2-fluoro-*N*-octadecylacetamide (**20**)



By following the general procedure 2 (GP2), starting from octadecyl isocyanate (290.5 mg, 0.34 mL, 1.0 mmol, 1.0 equiv), fluoroiodomethane (479.8 mg, 0.20 mL, 3.0 mmol, 3.0 equiv) and MeLi (1.75 mL of a solution 1.6 M in Et₂O, 2.8 mmol, 2.8 equiv) in dry THF/Et₂O (1:1 v/v, 5 mL), compound **20**^[18] was obtained in 91% yield (299.7 mg) as white solid (m.p.: 75-76 °C, lit^[18] 73-75 °C) after chromatography on silica gel (78:22 v/v, petroleum ether/ethyl acetate).


¹H-NMR (400 MHz, CDCl₃) δ: 6.31 (br, 1H), 4.77 (d, J = 47.6 Hz, 2H), 3.31 (q, J = 6.8 Hz, 2H), 1.53 (p, J = 7.1 Hz, 2H), 1.24 (s, 30H), 0.86 (t, J = 6.6 Hz, 3H).

¹³C-NMR (100 MHz, CDCl₃) δ: 167.54 (d, J = 17.0 Hz), 80.41 (d, J = 185.9 Hz), 39.04, 32.04, 29.78 (br), 29.75 (br), 29.68, 29.63, 29.60, 29.48, 29.36, 26.95, 22.80, 14.21.

¹⁹F-NMR (376 MHz, CDCl₃) δ: -224.00 (td, J = 47.7, 3.6 Hz).

HRMS (ESI), m/z: calc. for C₂₀H₄₀FNOH⁺: 330,3167 [M+H]⁺; found 330,3162.

N-cyclopentyl-2-fluoroacetamide (**21**)



By following the general procedure 2 (GP2), starting from cyclopentyl isocyanate (111.1 mg, 0.11 mL, 1.0 mmol, 1.0 equiv), fluoroiodomethane (479.8 mg, 0.20 mL, 3.0 mmol, 3.0 equiv) and MeLi (1.75 mL of a solution 1.6 M in Et₂O, 2.8 mmol, 2.8 equiv) in dry THF/Et₂O (1:1 v/v, 5 mL), compound **21**^[13] was obtained in 89% yield (129.2 mg) as white solid (m.p.: 61 °C, lit^[13] 60-31 °C) after chromatography on silica gel (95:5 v/v, DCM/ethyl acetate).


¹H-NMR (400 MHz, CDCl₃) δ: 6.22 (s, 1H), 4.74 (d, J = 47.4 Hz, 2H), 4.26 (h, J = 7.1 Hz, 1H), 2.00 (dtd, J = 12.0, 7.2, 2.8 Hz, 2H), 1.78 – 1.53 (m, 3H), 1.51 – 1.34 (m, 2H).

¹³C-NMR (100 MHz, CDCl₃) δ: 167.10 (d, J = 16.9 Hz), 80.39 (d, J = 185.9 Hz), 50.71, 33.10, 23.76.

¹⁹F-NMR (376 MHz, CDCl₃) δ: -224.10 (td, J = 48.0, 3.5 Hz).

HRMS (ESI), m/z: calc. for C₇H₁₂FNOH⁺: 146,0976 [M+H]⁺; found 146,0980.

N-cyclohexyl-2-fluoroacetamide (**22**)



By following the general procedure 2 (GP2), starting from cyclohexyl isocyanate (125.2 mg, 0.13 mL, 1.0 mmol, 1.0 equiv), fluoroiodomethane (479.8 mg, 0.20 mL, 3.0 mmol, 3.0 equiv) and MeLi (1.75 mL of a solution 1.6 M in Et₂O, 2.8 mmol, 2.8 equiv) in dry THF/Et₂O (1:1 v/v, 5 mL), compound **22**^[18] was obtained in 88% yield (140.1 mg) as white solid (m.p.: 101 °C, lit^[18] 99-101 °C) after chromatography on silica gel (95:5 v/v, DCM/ethyl acetate).


¹H-NMR (400 MHz, CDCl₃) δ: 6.14 (br, 1H), 4.76 (d, J = 47.4 Hz, 2H), 3.92 – 3.77 (m, 1H), 1.99 – 1.88 (m, 2H), 1.81 – 1.69 (m, 2H), 1.63 (m, 1H), 1.46 – 1.31 (m, 2H), 1.20 (m, 3H).

¹³C-NMR (100 MHz, CDCl₃) δ: 166.68 (d, J = 16.7 Hz), 80.42 (d, J = 186.0 Hz), 47.94, 33.15, 25.55, 24.92.

¹⁹F-NMR (376 MHz, CDCl₃) δ: -224.00 (td, J = 47.8, 3.6 Hz).

HRMS (ESI), m/z: calc. for C₈H₁₄FNOH⁺: 160,1132 [M+H]⁺; found 160,1127.

2-fluoro-*N*-((1*R*,4*R*)-4-methylcyclohexyl)acetamide (**23**)



By following the general procedure 2 (GP2), starting from trans-4-methylcyclohexyl isocyanate (139.2 mg, 1.0 mmol, 1.0 equiv), fluoroiodomethane (479.8 mg, 0.20 mL, 3.0 mmol, 3.0 equiv) and MeLi (1.75 mL of a solution 1.6 M in Et₂O, 2.8 mmol, 2.8 equiv) in dry THF/Et₂O (1:1 v/v, 5 mL), compound **23** was obtained in 86% yield (148.9 mg) as white solid (m.p.: 131 °C) after chromatography on silica gel (95:5 v/v, DCM/ethyl acetate).


¹H-NMR (400 MHz, CDCl₃) δ: 6.07 (rb, 1H), 4.75 (d, J = 47.4 Hz, 2H), 3.78 (qdd, J = 11.7, 5.7, 2.5 Hz, 1H), 2.06 – 1.92 (m, 2H), 1.77 – 1.69 (m, 2H), 1.34 (tdq, J = 13.0, 6.5, 3.4 Hz, 1H), 1.25 – 0.97 (m, 4H), 0.89 (d, J = 6.5 Hz, 3H).

¹³C-NMR (100 MHz, CDCl₃) δ: 166.79 (d, J = 16.9 Hz), 80.41 (d, J = 186.0 Hz), 48.22, 33.86, 33.17, 31.99, 22.24.

¹⁹F-NMR (376 MHz, CDCl₃) δ: -224.00 (td, J = 47.6, 3.2 Hz).

HRMS (ESI), m/z: calc. for C₉H₁₆FNOH⁺: 174,1289 [M+H]⁺; found 174,1281.

N-(adamantan-1-yl)-2-fluoroacetamide (**24**)



By following the general procedure 2 (GP2), starting from 1-adamantyl isocyanate (177,2 mg, 1.0 mmol, 1.0 equiv), fluoroiodomethane (479.8 mg, 0.20 mL, 3.0 mmol, 3.0 equiv) and MeLi (1.75 mL of a solution 1.6 M

in Et₂O, 2.8 mmol, 2.8 equiv) in dry THF/Et₂O (1:1 v/v, 5 mL), compound **24**^[19] was obtained in 85% yield (179.6 mg) as white solid (m.p.: 178-179 °C) after chromatography on silica gel (82:18 v/v, petroleum ether/ethyl acetate).


¹H-NMR (400 MHz, CDCl₃) δ: 5.91 (br, 1H), 4.64 (d, J = 47.7 Hz, 2H), 2.10 (s, 3H), 2.04 (s, 6H), 1.69 (s, 6H).

¹³C-NMR (100 MHz, CDCl₃) δ: 166.39 (d, J = 15.4 Hz), 80.20 (d, J = 187.5 Hz), 52.13, 41.61, 36.23, 29.42.

¹⁹F-NMR (376 MHz, CDCl₃) δ: δ -220.00 (td, J = 47.7, 4.1 Hz).

HRMS (ESI), m/z: calc. for C₁₂H₁₈FNOH⁺: 212,1445 [M+H]⁺; found 212,1452.

N-(2,6-dimethylphenyl)-2-fluoroacetamide (**25**)



By following the general procedure 2 (GP2), starting from 2,6-dimethylphenyl isocyanate (147,2 mg, 0.14 mmol, 1.0 mmol, 1.0 equiv), fluoroiodomethane (479.8 mg, 0.20 mL, 3.0 mmol, 3.0 equiv) and MeLi (1.75 mL of a solution 1.6 M in Et₂O, 2.8 mmol, 2.8 equiv) in dry THF/Et₂O (1:1 v/v, 5 mL), compound **25** was obtained in 88% yield (159.5 mg) as white solid (m.p.: 136 °C) after chromatography on silica gel (72:28 v/v, petroleum ether/ethyl acetate).


¹H-NMR (400 MHz, CDCl₃) δ: 7.62 (br, 1H), 7.18 – 7.06 (m, 3H), 4.97 (d, J = 47.5 Hz, 2H), 2.23 (s, 6H).

¹³C-NMR (100 MHz, CDCl₃) δ: 166.06 (d, J = 16.9 Hz), 135.47, 132.19, 128.37, 127.84, 80.49 (d, J = 186.4 Hz), 18.32.

¹⁹F-NMR (376 MHz, CDCl₃) δ: -222.56 (td, J = 47.7, 4.1 Hz).

HRMS (ESI), m/z: calc. for C₁₀H₁₂FNOH⁺: 182,0976 [M+H]⁺; found 182,0971.

N-(2,4,6-trimethylphenyl)-2-fluoroacetamide (**26**)



By following the general procedure 2 (GP2), starting from 2,4,6-trimethylphenyl isocyanate (161,2 mg, 1.0 mmol, 1.0 equiv), fluoroiodomethane (479.8 mg, 0.20 mL, 3.0 mmol, 3.0 equiv) and MeLi (1.75 mL of a solution 1.6 M in Et₂O, 2.8 mmol, 2.8 equiv) in dry THF/Et₂O (1:1 v/v, 5 mL), compound **26**^[20] was obtained in 87% yield (169.7 mg) as white solid (m.p.: 148 °C) after chromatography on silica gel (75:25 v/v, petroleum ether/ethyl acetate).


¹H-NMR (400 MHz, CDCl₃) δ: 7.54 (br, 1H), 6.92 (s, 2H), 4.97 (d, J = 47.4 Hz, 2H), 2.29 (s, 3H), 2.19 (s, 6H).

¹³C-NMR (100 MHz, CDCl₃) δ: 166.21 (d, J = 16.8 Hz), 137.55, 135.17, 129.50, 129.10, 80.53 (d, J = 186.4 Hz), 20.95, 18.21.

¹⁹F-NMR (376 MHz, CDCl₃) δ: -222.68 (td, J = 47.2, 4.1 Hz).

HRMS (ESI), m/z: calc. for C₁₁H₁₄FNOH⁺: 196,1132 [M+H]⁺; found 196,1138.

N-(2,6-diisopropylphenyl)-2-fluoroacetamide (**27**)



By following the general procedure 2 (GP2), starting from 2,6-diisopropylphenyl isocyanate (203.3 mg, 0.21 mL, 1.0 mmol, 1.0 equiv), fluoroiodomethane (479.8 mg, 0.20 mL, 3.0 mmol, 3.0 equiv) and MeLi (1.75 mL of a solution 1.6 M in Et₂O, 2.8 mmol, 2.8 equiv) in dry THF/Et₂O (1:1 v/v, 5 mL), compound **27** was obtained in 91% yield (215.9 mg) as white solid (m.p.: 134 °C) after chromatography on silica gel (85:15 v/v, petroleum ether/ethyl acetate).


¹H-NMR (400 MHz, CDCl₃) δ: 7.45 (br, 1H), 7.25 (t, J = 7.7 Hz, 1H), 7.12 (d, J = 7.7 Hz, 2H), 4.93 (d, J = 47.5 Hz, 2H), 2.97 (hept, J = 6.9 Hz, 2H), 1.14 (d, J = 7.0 Hz, 12H).

¹³C-NMR (100 MHz, CDCl₃) δ: 167.13 (d, J = 16.7 Hz), 146.28, 129.37, 128.96, 123.80, 80.69 (d, J = 186.4 Hz), 28.97, 23.70.

¹⁹F-NMR (376 MHz, CDCl₃) δ: -222.49 (td, J = 47.6, 4.1 Hz).

HRMS (ESI), m/z: calc. for C₁₄H₂₀FNOH⁺: 237,1529 [M+H]⁺; found 237,1525.

***N*-(2-(*tert*-butyl)phenyl)-2-fluoroacetamide (**28**)**



By following the general procedure 2 (GP2), starting from 2-(*tert*-butyl)phenylisocyanate (175,2 mg, 0.18 mL, 1.0 mmol, 1.0 equiv), fluoroiodomethane (479.8 mg, 0.20 mL, 3.0 mmol, 3.0 equiv) and MeLi (1.75 mL of a solution 1.6 M in Et₂O, 2.8 mmol, 2.8 equiv) in dry THF/Et₂O (1:1 v/v, 5 mL), compound **28** was obtained in 88% yield (167.3 mg) as white solid (m.p.: 123 °C) after chromatography on silica gel (80:20 v/v, petroleum ether/ethyl acetate).

¹H-NMR (400 MHz, CDCl₃) δ: 8.14 (br, 1H), 7.74 (dd, J = 7.9, 1.6 Hz, 1H), 7.40 (dd, J = 7.9, 1.7 Hz, 1H), 7.24 (td, J = 7.5, 1.7 Hz, 1H), 7.17 (td, J = 7.6, 1.6 Hz, 1H), 4.96 (d, J = 47.5 Hz, 2H), 1.41 (s, 9H).





¹³C-NMR (100 MHz, CDCl₃) δ: 165.58 (d, J = 16.2 Hz), 142.05, 133.86, 127.03, 126.79, 126.63, 126.49, 80.65 (d, J = 186.9 Hz), 34.58, 30.71.




¹⁹F-NMR (376 MHz, CDCl₃) δ: -222.60 (td, J = 47.4, 5.1 Hz).

HRMS (ESI), m/z: calc. for C₁₂H₁₆FNOH⁺: 210,1289 [M+H]⁺; found 210,1285.


Copies of ^1H , ^{13}C and ^{19}F -NMR copies of all compounds

2-fluoro-*N*-(4-fluorophenyl)acetamide (2)







1,3-bis(4-fluorophenyl)urea (2a)





2.50 DMSO-d6







(¹³C-NMR, DMSO-d₆, 150 MHz)

158.2
156.6
152.8
136.0
136.0
120.1
120.0
115.3
115.2




(¹⁹F-NMR, DMSO-d₆, 376 MHz)



-121.4
-121.5
-121.5
-121.5
-121.5
-121.5
-121.5




1,3,5-tris(4-fluorophenyl)biuret (2b)




(¹H-NMR, CDCl₃, 400 MHz)






(¹³C-NMR, CDCl₃, 100 MHz)






(¹⁹F-NMR, CDCl₃, 376 MHz)

109.9
-110.0
-110.0
-110.0
-117.6




2-bromo-N-(4-fluorophenyl)acetamide (2c)




(¹H-NMR, CDCl₃, 400 MHz)


8.17
7.50
7.49
7.49
7.46
7.47
3.26, CDCl₃
2.06
2.04
2.04
2.02




4.01






2-fluoro-N-(4-iodophenyl)acetamide (3)








2-fluoro-N-(p-tolyl)acetamide (4)





(¹H-NMR, CDCl₃, 400 MHz)






(¹³C-NMR, CDCl₃, 100 MHz)





N-(2-ethylphenyl)-2-fluoroacetamide (5)





(¹³C-NMR, CDCl₃, 100 MHz)



165.8
165.7

135.0
133.7
128.9
127.0
126.2
123.3

81.2
80.0
77.2 CHLOROFORM-D

24.3

14.0





(¹⁹F-NMR, CDCl₃, 376 MHz)


-221.9
-221.9
-222.0
-222.1
-222.2
-222.2

-221.9
-221.9
-222.0
-222.1
-222.2
-222.2


-221.0 -221.5 -222.0 -222.5 -223.0




2-fluoro-N-(4-(methylthio)phenyl)acetamide (6)





(¹H-NMR, CDCl₃, 400 MHz)





(¹³C-NMR, CDCl₃, 100 MHz)






2-fluoro-N-(naphthalen-1-yl)acetamide (7)





166.3
166.1

134.2
130.8
129.0
127.0
126.7
126.5
126.3
120.9
120.3



81.7
79.8
77.2 CDCl₃




(¹³C-NMR, CDCl₃, 100 MHz)






(¹⁹F-NMR, CDCl₃, 376 MHz)




(R)-2-fluoro-N-(1-phenylethyl)acetamide ((R)-9)





(¹H-NMR, CDCl₃, 400 MHz)






(¹³C-NMR, CDCl₃, 100 MHz)






(S)-2-fluoro-N-(1-phenylethyl)acetamide ((S)-9)







(¹³C-NMR, CDCl₃, 100 MHz)





(¹⁹F-NMR, CDCl₃, 376 MHz)




2-fluoro-N-(1-phenylethyl)acetamide ((rac)-9)





(¹H-NMR, CDCl₃, 400 MHz)




(¹³C-NMR, CDCl₃, 100 MHz)








224.3
 224.3
 224.4
 224.4
 224.5
 224.5





(S)-2-fluoro-N-(1-phenylpropyl)acetamide ((S)-10)






(¹³C-NMR, CDCl₃, 100 MHz)





(¹⁹F-NMR, CDCl₃, 376 MHz)




2-fluoro-N-(1-phenylpropyl)acetamide ((rac)-10)





(¹H-NMR, CDCl₃, 400 MHz)




(¹³C-NMR, CDCl₃, 100 MHz)










224.2
 224.2
 224.3
 224.3
 224.4
 224.4




((R)-2-fluoro-N-(1-(naphthalen-1-yl)ethyl)acetamide ((R)-11)








((S)-2-fluoro-N-(1-(naphthalen-1-yl)ethyl)acetamide ((S)-11)




(¹H-NMR, CDCl₃, 400 MHz)





(¹³C-NMR, CDCl₃, 100 MHz)










(¹³C-NMR, CDCl₃, 150 MHz)






(¹⁹F-NMR, CDCl₃, 376 MHz)










N-benzhydryl-2-fluoroacetamide (12)






2-fluoro-N-(2-(3-(prop-1-en-2-yl)phenyl)propan-2-yl)acetamide (13)








***N,N'*-(1,3-phenylenebis(propane-2,2-diyl))bis(2-fluoroacetamide) (14)**




(¹H-NMR, CDCl₃, 400 MHz)




(¹³C-NMR, CDCl₃, 100 MHz)







(¹⁹F-NMR, CDCl₃, 376 MHz)



-220.9
-220.9
-221.0
-221.1
-221.1




N-benzyl-2-fluoroacetamide (15)




(¹H-NMR, CDCl₃, 400 MHz)

7.37
7.36
7.35
7.35
7.34
7.34
7.33
7.31
7.30
7.29
7.28
7.28
7.26
7.26
6.70

4.88
4.76
4.51
4.50






167.7
167.5



137.5
128.9
127.9
127.9

81.3
77.2
77.2 CDCl₃


43.0





224.4
224.4
224.5
224.5
224.6
224.6




2-fluoro-N-(4-methoxybenzyl)acetamide (16)




(¹H-NMR, CDCl₃, 400 MHz)





(¹³C-NMR, CDCl₃, 100 MHz)







(¹⁹F-NMR, CDCl₃, 376 MHz)








2-fluoro-N-phenethylacetamide (17)




(¹H-NMR, CDCl₃, 400 MHz)








2-fluoro-N-(2-(thiophen-2-yl)ethyl)acetamide (18)




(¹H-NMR, CDCl₃, 400 MHz)





(¹³C-NMR, CDCl₃, 100 MHz)







(¹⁹F-NMR, CDCl₃, 376 MHz)







(2-fluoroacetyl)-L-phenylalanine *tert*-butyl ester (19)










(¹H-NMR, CDCl₃, 600 MHz)






2-fluoro-N-octadecylacetamide (20)










N-cyclopentyl-2-fluoroacetamide (21)




(1H-NMR, CDCl3, 400 MHz)










N-cyclohexyl-2-fluoroacetamide (22)




(¹H-NMR, CDCl₃, 400 MHz)






2-fluoro-N-((1R,4R)-4-methylcyclohexyl)acetamide (23)


7.26 CDCl3
 6.07
 4.81
 4.69
 3.82
 3.81
 3.81
 3.80
 3.79
 3.78
 3.77
 3.76
 3.75
 3.74
 3.73
 3.72
 1.99
 1.98
 1.96
 1.95
 1.95
 1.75
 1.74
 1.72
 1.71
 1.71
 1.40
 1.39
 1.38
 1.37
 1.36
 1.36
 1.35
 1.34
 1.33
 1.33
 1.32
 1.31
 1.31
 1.30
 1.29
 1.28
 1.28
 1.27
 1.26
 1.20
 1.20
 1.17
 1.17
 1.14
 1.14
 1.11
 1.11
 1.10
 1.08
 1.07
 1.05
 1.04
 1.03
 1.01
 1.01
 0.90
 0.89




(¹H-NMR, CDCl₃, 400 MHz)






166.9
 165.7
 81.3
 79.5
 77.2 CDCl3
 48.2
 33.9
 33.2
 32.0
 22.2






(¹³C-NMR, CDCl₃, 100 MHz)







***N*-(adamantan-1-yl)-2-fluoroacetamide (24)**








(¹³C-NMR, CDCl₃, 100 MHz)





(¹⁹F-NMR, CDCl₃, 376 MHz)




***N*-(2,6-dimethylphenyl)-2-fluoroacetamide (25)**




(¹H-NMR, CDCl₃, 400 MHz)




(¹³C-NMR, CDCl₃, 100 MHz)







(¹⁹F-NMR, CDCl₃, 376 MHz)





-222.4
-222.4
-222.6
-222.6
-222.7
-222.7




N-(2,4,6-trimethylphenyl)-2-fluoroacetamide (26)




(¹H-NMR, CDCl₃, 400 MHz)




(¹³C-NMR, CDCl₃, 100 MHz)







(¹⁹F-NMR, CDCl₃, 376 MHz)




-222.5
-222.6
-222.7
-222.8
-222.8



N-(2,6-diisopropylphenyl)-2-fluoroacetamide (25)



(¹H-NMR, CDCl₃, 400 MHz)




7.45
7.27
7.25
7.23
7.13
7.11



4.99
4.87

3.02
3.00
2.97
2.95
2.93
2.92


1.14
1.13
1.10




(¹³C-NMR, CDCl₃, 100 MHz)





(¹⁹F-NMR, CDCl₃, 376 MHz)




N-(2-(*tert*-butyl)phenyl)-2-fluoroacetamide (28)




(¹H-NMR, CDCl₃, 400 MHz)




(¹³C-NMR, CDCl₃, 100 MHz)






(¹⁹F-NMR, CDCl₃, 376 MHz)




-222.5
-222.5
-222.6
-222.6
-222.7
-222.7



HPLC Analysis Data for chiral compounds


Racemate (rac)-9



Chiralpak IA, Isocratic, *n*-hex:*i*-PrOH 95:5, 1mL/min, λ 210 nm

Peaks	Retention time (min)	Area	Area%
1	8,467	23247315	52,175
2	9,627	21308909	47,825
Tot		44556224	100,000


Enantioenriched (R)-9 $[\alpha]_D^{25} = +39.6^\circ$ (c 0.81 MeOH), lit.^[21] $[\alpha]_D^{25} = +45.5^\circ$ (c 0.96 MeOH).



Chiralpak IA, Isocratic, *n*-hex:*i*-PrOH 95:5, 1mL/min, λ 210 nm

Peaks	Retention time (min)	Area	Area%
1	8,560	9785853	99,217
2	9,813	77228	0,783
Tot		9863081	100,000


Enantioenriched (S)-9 $[\alpha]_D^{25} = -28.2^\circ$ (c 0.72 MeOH).



Chiralpak IA, Isocratic, *n*-hex:*i*-PrOH 95:5, 1mL/min, λ 210 nm

Peaks	Retention time (min)	Area	Area%
1	8,643	95946	0,777
2	9,740	12254832	99,223
Tot		12350778	100,000


Racemate (rac)-10



Chiralpak IC, Isocratic, *n*-hex:*i*-PrOH, 0.9 mL/min, λ 254 nm


Peaks	Retention time (min)	Area	Area%
1	9,649	454624	49,782
2	11,152	458607	50,218
Tot		913231	100,000

Enantioenriched (*S*)-10 [α]_D²⁵ = - 37.6 ° (c 0.53 MeOH).



Peaks	Retention time (min)	Area	Area%
1	9,226	2479623	99,241
2	10,676	18967	0,759
Tot		2498590	100,000


Racemate (rac)-11



Chiralpak IG, Isocratic, *n*-hex:*i*-PrOH, 0.80 mL/min, λ 220 nm.


Peaks	Retention time (min)	Area	Area%
1	21,060	23607149	49,428
2	24,915	24153097	50,572
Tot		47760246	100,000

Enantioenriched (R)-11 $[\alpha]_D^{25} = +22.6^\circ$ (c 0.32 CHCl₃).



Peaks	Retention time (min)	Area	Area%
1	21,412	15631164	98,854
2	26,002	181160	1,146
Tot		15812324	100,000

Enantioenriched (S)-11 $[\alpha]_D^{25} = -18.5^\circ$ (c 0.24 CHCl₃)



Peaks	Retention time (min)	Area	Area%
1	21,518	57751	0,219
2	25,392	26285214	99,781
Tot		26342965	100,000

References

- [1] Z. J. Shen, C. Zhu, X. Zhang, C. Yang, M. Rueping, L. Guo, W. Xia, *Angewandte Chemie* **2023**, *135*, e202217244.
- [2] U. K. Das, A. Kumar, Y. Ben-David, M. A. Iron, D. Milstein, *Journal of the American Chemical Society* **2019**, *141*, 12962-12966.
- [3] L. Wang, H. Wang, G. Li, S. Min, F. Xiang, S. Liu, W. Zheng, *Advanced Synthesis & Catalysis* **2018**, *360*, 4585-4593.
- [4] A. I. McKay, W. A. Altalhi, L. E. McInnes, M. L. Czyn, A. J. Canty, P. S. Donnelly, R. A. O'Hair, *The Journal of Organic Chemistry* **2020**, *85*, 2680-2687.
- [5] F. Weigert, *The Journal of Organic Chemistry* **1973**, *38*, 1316-1319.
- [6] S. Faiz, A. F. Zahoor, M. Ajmal, S. Kamal, S. Ahmad, A. M. Abdelgawad, M. E. Elnaggar, *Journal of Heterocyclic Chemistry* **2019**, *56*, 2839-2852.
- [7] S. J. Ratnakar, M. Woods, A. J. Lubag, Z. Kovács, A. D. Sherry, *Journal of the American Chemical Society* **2008**, *130*, 6-7.
- [8] T. Nakamura, Y. Hamamoto, T. Ito, *Nippon Nogeikagaku Kaishi* **1965**, *39*, 420-426.
- [9] C. C. Price, W. G. Jackson, *Journal of the American Chemical Society* **1947**, *69*, 1065-1068.
- [10] E. D. Bergmann, P. Moses, M. Neeman, *Journal of the Science of Food and Agriculture* **1957**, *8*, 400-404.
- [11] K. Aoki, K. Koga, *Chemical and Pharmaceutical Bulletin* **2000**, *48*, 571-574.
- [12] P. D. Bailey, A. N. Boa, J. Clayson, *Tetrahedron* **2009**, *65*, 1724-1736.
- [13] S. Mišćević, D. Minić, S. Petrović, *Journal of fluorine chemistry* **1992**, *59*, 239-247.
- [14] S. H. Doan, M. A. Hussein, T. V. Nguyen, *Chemical Communications* **2021**, *57*, 8901-8904.
- [15] L. S. Munaretto, R. D. Gallo, L. P. M. Leão, I. D. Jurberg, *Organic & Biomolecular Chemistry* **2022**, *20*, 6178-6182.
- [16] D. Lafrance, P. Bowles, K. Leeman, R. Rafka, *Organic Letters* **2011**, *13*, 2322-2325.
- [17] Z. Lyu, Y. Zhao, Z. Y. Buuh, N. Gorman, A. R. Goldman, M. S. Islam, H.-Y. Tang, R. E. Wang, *Journal of the American Chemical Society* **2021**, *143*, 1341-1347.
- [18] J. Bacon, C. Bradley, E. Hoegberg, P. Tarrant, J. Cassaday, *Journal of the American Chemical Society* **1948**, *70*, 2653-2655.
- [19] J. Wettergren, T. Ankner, G. Hilmersson, *Chemical Communications* **2010**, *46*, 7596-7598.
- [20] S. Chen, P. Gan, Y. Qian, R. Yao, Y. Hu, B. Shao, S. Xiao, C. Zhan, Y. Xu, *Yao xue xue bao = Acta pharmaceutica Sinica* **1982**, *17*, 674-681.
- [21] K. Aoki, K. Koga, *Chem. Pharm. Bull.* **2000**, *48*, 571-574.